Announced in March this year, the deal also requires Boston Scientific to make an additional payment of $50m based on sales in 2016.
The acquired portfolio includes GreenLight XPS and HPS Laser Therapy systems designed to treat benign prostatic hyperplasia, AMS 800 Urinary Control system for male incontinence and AMS 700 Inflatable Penile Prosthesis used for erectile dysfunction.
According to Boston Scientific, AMS’ women’s health business was not included in the deal.
Boston Scientific urology and pelvic health president Karen Prange said: "Together, we create a business with nearly $1bn in annual sales, strong future growth prospects through innovation and market expansion, and a significant opportunity to address unmet medical needs.
"As a category leader, our combined organisation will bring value-driven innovations that can help healthcare providers advance patient outcomes, reduce procedure costs, enhance quality and evolve the treatment of urologic and pelvic conditions in ways that previously could not be realised by either company alone."
The company is expected to incorporate the acquisitions in its urology and women’s health businesses. The joint entity will be called Boston Scientific Urology and Pelvic Health business.
This business unit will continue to invest in surgical solutions for the treatment of abnormal uterine bleeding and uterine fibroids.
These new technologies complement Boston Scientifics’ urology portfolio to treat kidney stones and pelvic floor disorders, enabling further innovation for the company across five common urologic diseases that account for 50% of all urologic surgical procedures.